Review anchor
Dual specificity mitogen-activated protein kinase kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Dual specificity mitogen-activated protein kinase kinase 3
CHEMBL2109
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity mitogen-activated protein kinase kinase 3 as ChEMBL target CHEMBL2109, mapped to UniProt P46734. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2109
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P46734
Dual specificity mitogen-activated protein kinase kinase 3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Dual specificity mitogen-activated protein kinase kinase 3 matters
Dual specificity mitogen-activated protein kinase kinase 3 is reviewed as Dual specificity mitogen-activated protein kinase kinase 3 (UniProt P46734); the current evidence base includes 7 approved drugs, 556 compounds, and 205 assays, with lead potency reaching pChEMBL 8.6.
Protein context
Dual specificity mitogen-activated protein kinase kinase 3
Dual specificity mitogen-activated protein kinase kinase 3 Sequence length is 347 aa.
Review this target as Dual specificity mitogen-activated protein kinase kinase 3, mapped to UniProt P46734. Sequence length is 347 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P46734
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 7 approved drugs, 556 compounds, and 205 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 8.6.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 8.6).
Activity source · ChEMBL 36 via Core Engine
7 approved
pChEMBL 8.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Dual specificity mitogen-activated protein kinase kinase 3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P46734, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
556
Total Compounds
205
Total Assays
7
Approved Drugs
IC50: 25.0, KI: 1.0, KD: 365.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL3752910
|
8.4 | Kd | — |
|
|
No preferred name
CHEMBL3747095
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL3746157
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL388978
|
8.3 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
Source Header